We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Signaling Regulatory Protein Found That Mediates Metastasis of Human Colorectal Cancer Cells

By LabMedica International staff writers
Posted on 09 Jul 2013
The direct effect of the signaling regulatory protein km23-1 (also called DYNLRB1/mLC7-1/robl-1/Dnlc2a/DYRB1) on TGF-beta (transforming growth factor beta) defines its role in mediating the migration, invasion, and tumor growth of human colorectal carcinoma (CRC) cells.

TGF-beta acts as an antiproliferative factor in normal epithelial cells and at early stages of cancer development. More...
However, when a cell is transformed into a cancer cell, parts of the TGF-beta signaling pathway are mutated, and TGF-beta no longer controls the cell. These cancer cells and surrounding stromal cells (fibroblasts) begin to proliferate. Both types of cell increase their production of TGF-beta. This TGF-beta acts on the surrounding stromal cells, immune cells, endothelial, and smooth muscle cells causing immunosuppression and angiogenesis, which makes the cancer more invasive.

Investigators at the Pennsylvania State College of Medicine (Hershey, USA) had previously described km23-1 as a novel modulator of the actin cytoskeleton that also regulated the Ras oncogene and mitogen-activated protein kinase activities in TGF-beta-sensitive epithelial cells.

In a new study, the investigators examined the functional role of this signaling regulatory protein in mediating the migration, invasion, and tumor growth of human CRC cells. Towards this end, they used small interfering RNA (siRNA) to deplete levels of km23-1 in cultures of human CRC cells.

They reported in the June 3, 2013, online edition of the journal PLOS ONE that depletion of km23-1 inhibited constitutive extracellular signal-regulated kinase (ERK) activation, as well as proinvasive ERK effector functions that included TGF-beta promoter transactivation, and TGF-beta secretion. In addition, knockdown of km23-1 reduced the paracrine effects of CRC cell-secreted factors in conditioned medium and in fibroblast co-cultures. Furthermore, km23-1 depletion in human CRC cells reduced cell migration and invasion, as well as expression of the ERK-regulated, metastasis-associated scaffold protein Ezrin. Km23-1 inhibition significantly suppressed tumor formation in an in vivo model system.

"The type of cell movement, or migration, has important implications with respect to the detection of tumor cells in the blood of cancer patients, as well as for the development of new treatments," said senior author Dr. Kathleen M. Mulder, professor of biochemistry and molecular biology at Pennsylvania State College of Medicine. "Km23-1 may be able to help in this process due to its role in the assembly of large groups of proteins favorable to cancer invasion. If we can block km23-1, we can stop the spread of colon cancer earlier, but we would also affect other important functions of the protein. In order to address this issue, we are now trying to find the specific partners of km23-1 that contribute to the invasion of the cancer cells. Then we can design more precise therapeutic agents that target critical regions of km23-1 rather than eliminating the entire protein."

Related Links:

Pennsylvania State College of Medicine




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Rapid Flu Test
Influenza A&B Rapid Test Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.